x
NBC logotype

2022-09-08

8.50–9.00

Welcome

9.00–10.30

Symposium 4a

Nordic biobanks roles in pandemic

In this session different ways to utilize biobanks in Covid19 research will be described, such as the collection of new samples to study long covid, linking genomic biobank data with hospital and register data to provide insight into disease development, and how the biobank infrastructure was harnessed to develop mass testing of covid19 in the population. These provide good examples for how biobank infrastructures can support the study of emerging pandemics.

Invited speakers

Markus Perola, Research Professor, THL Biobank, Finland

Utilizing Finnish biobanks in Covid19 research 


Karina Meden Sørensen, Section Leader, Laboratory Manager, Statens Seruminstitut, SSI, Denmark


2 Oral Abstract presenters, to be announced.

Chair: tba

9.00–10.30

Symposium 4b

Good examples of biobank research

As Biobanks can give researchers access to samples from a large number of people they have become a very efficient and important resource in medical research. Thus, they are supporting cutting edge research in e.g. genomics and personalized medicine. The session will provide a broad perspective as well as specific examples on excellent research based on biobanks.

Invited speakers

Mark Divers, PhD, Director Karolinska Institutet Biobank, Sweden

Biobanks make a difference: why Time magazine and Forbes got it right


Jonas Ghouse, MD, PhD, Laboratory of Molecular Cardiology, Copenhagen University Hospital, Denmark

Use of genetic profiling of a large biobank combined with prescription patterns to discover genetic loci associated with adverse drug reactions


2 Oral Abstract presenters, to be announced.

Chair: Erik Sørensen, MSc, PhD, Operational Director Copenhagen Hospital Biobank Unit

10.30–11.00

Coffee break – Exhibition & Posters

11.00–12.30

Symposium 5a

Infrastructure

The infrastructure of Biobank Sweden aims to give Sweden the best prerequisites for healthcare and research within the biobank area, both national and international. 

AstraZeneca’s vision is a global biobank infrastructure with visibility, in full compliance with ethical and legal standards and rapid access to samples.

In this session we will also address the EU clinical trial regulation, which came into force in January 2022, and discuss some of the obvious possibilities and hidden obstacles in getting the much-needed infrastructure in place.

Invited speakers

Sonja Eaker Fält, PhD, Head of Biobank Sweden

Biobank Sweden, a national infrastructure with regional availability


Karin Gedda, PhD, Associate Director from AstraZeneca, Sweden

Biobanking from a global perspective


2 Oral Abstract presenters, to be announced.

Chair: Camilla Hildesjö, Med Lic, Custodian Biobank Östergötland, Regionalt Biobankscentrum, Linköping, Sweden

11.00–12.30

Symposium 5b

Patient engagement and return of genomic data

Summary: tba

Invited speakers

Vigdis Stefansdottir, MD, University of Iceland, Iceland


Margareta Haag, Chair of the network against cancer, Sweden


2 Oral Abstract presenters, to be announced.

Chair: Jon Johannes Jonsson, professor, University of Iceland, Iceland

12.30–13.30

General Lunch in Exhibit Hall – Exhibition & Posters

13.30–15.00

Symposium 6a

Digitalization

What can digitalization offer biobanks and biobank research? New ways to visualize vast amounts of data, explore different scenarios and obtain novel research ideas will be shown, including health register data and genomic data. In addition, developing digital services for biobank sample donors, built inside the hospital settings will be described. These include consent management and recontact of donors.

Invited speakers

Aki Lehto (ICT-Architect), Tampere University Hospital, Finland

OmaTays – enabling digital consent interaction for Tampere Biobank


Toni Mikkola, Data Scientist, Tampere University Hospital, Finland

Short introduction to unstructured patient records, – From regular expressions to text classification


2 Oral Abstract presenters, to be announced.

Chair: Kimmo Savinainen, Deputy Head of Finnish Clinical Biobank Tampere, Tampere University Hospital, Finland

13.30–15.00

Symposium 6b

Innovative technologies

New developments from all directions are transforming biobanking and making it possible to do so much more with samples and data that represent complex biology. This symposium will look at some examples of technology leaps that either build on biobanks or transform what they can do.

Invited speakers

Mattias Rantalainen, Lecturer Senior, Karolinska Institutet, Sweden


Päivi Östling, Researcher, Karolinska Institutet, Sweden

Material flows needed for multi-onic and functional precision medicine.


2 Oral Abstract presenters, to be announced.

Chair: Mark Divers, BSc PhD, Director, Karolinska Institutet Biobank, Sweden

15.00–15.20

Coffee break – Exhibition & Posters

15.20–16.05

Panel discussion – Collaboration between Nordic Biobanks

Moderator:

Frida Lundmark, The Swedish Association of the Pharmaceutical Industry, LIF

Panel:

Sweden: Sonja Eaker Fält, Biobank Sweden
Norway: Kristian Hveem, NTNU, Biobank Norway
Denmark: Lasse Boding, Danish National Biobank
Finland: Sirpa Soini, THL Biobank, Finland
Iceland: Jon Jonsson, University of Iceland, Iceland

16.05–16.15

Wrap up the day